Ardelyx to Present at the Jefferies 2020 Virtual Healthcare Conference

News

  View printer-friendly version

<<  Back
Ardelyx to Present at the Jefferies 2020 Virtual Healthcare Conference

FREMONT, Calif., May 26, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced that Mike Raab, president and chief executive officer of Ardelyx, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020 at 3:00 p.m. ET.

To access the live webcast of Ardelyx's presentation please visit the Events & Presentations page within the Investor section of the Ardelyx website at ir.ardelyx.com. A replay of the webcast will be available on the Ardelyx website for 60 days following the conference.

About Ardelyx, Inc.
Ardelyx is focused on enhancing the way people with kidney and cardiovascular diseases are treated by developing innovative first-in-class medicines. Ardelyx's pipeline includes tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis, for which the Company is preparing for NDA submission mid-year, and RDX013, a potassium secretagogue program for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. In addition, Ardelyx received FDA approval of IBSRELA® (tenapanor) on September 12, 2019. Ardelyx has established agreements with Kyowa Kirin Corporation in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and commercialization of tenapanor in the respective territories.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/ardelyx-to-present-at-the-jefferies-2020-virtual-healthcare-conference-301064956.html

SOURCE Ardelyx

Investor and Media Contact: Kimia Keshtbod, 510-745-1751, kkeshtbod@ardelyx.com, OR Sylvia Wheeler, Wheelhouse Life Science Advisors, swheeler@wheelhouselsa.com, OR Alex Santos, Wheelhouse Life Science Advisors, asantos@wheelhouselsa.com